Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: A prospective trial

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 1, Issue 2, 1996, Pages 107-116

  Stein, Evan A ^a   Davidson, Michael H ^b   Dujovne, Carlos A ^c   Hunninghake, Donald B ^d   Goldberg, Ronald B ^e   Illingworth, D Roger ^f   Knopp, Robert H ^g   Miller, Valery T ^h   Frost, Philip ⁱ   Isaacsohn, Jonathan L ^j   Mitchel, Yale B ^k   Melino, Michael R ^k   Shapiro, Deborah ^k   Tobert, Jonathan A ^k  

^a Medical Research Laboratories   (United States)

^b RADIANT RESEARCH   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^h GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j CHRIST HOSPITAL   (United States)

^k MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

HMG CoA reductase inhibitor; Hypercholesterolemia

Indexed keywords

EID: 0000369454     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/107424849600100204     Document Type: Article

References (37)

1. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: Reduction in incidence of coronary heart disease. JAMA 251:351, 1984.
2. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P,et al.Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237, 1987.
3. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4s). Lancet 344:1383, 1991.
4. Fievet C, Fruchart JC. HDL heterogeneity and coronary heart disease. Diabetes Metab Rev 7:155, 1991.
5. Buring JE, O'Connor GT, Goldhaber SZ, Rosner B, Herbert PN, Blum CB,et al.Decreased HDL2 and HDL3 cholesterol, apo A-I and apo A-II, and increased risk of myocardial infarction. Circulation 85:22, 1992.
6. Puchois P, Kandoussi A, Fievet P, Foumer JL, Bertrand M, Koren E,et al.Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 68:35, 1987.
7. Fruchart JC, Alihaud G. Apolipoprotein A-containing lipoprotein particles: Physiological role, quantification, and clinical significance. Clin Chem 38:793, 1992.
8. Expert Panel on Detection. Evaluation. and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel 11). JAMA 269:3015, 1993.
9. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24, 1988.
10. Drood JM, Zimetbaum PJ, Frishman WH. Nicotinic acid for the treatment of hyperlipoproteinemia. J Clin Pharmacol 31:641, 1991.
11. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH.et al.Comparative effects of lovastatin and niacin in primary hypercholesterolemia. Arch Intern Med 154:1586, 1994.
12. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231:360, 1975.
13. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ,et al.Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 8:1245, 1986.
14. Frick MH, Elo OE, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317:1237, 1987.
15. Grundy SM, Vega GL. Fibric acids: Effects on lipids and lipoprotein metabolism, Am J Med 83(suppl 5B):9, 1987.
16. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: A new look at old data. Circulation 91:2274, 1995.
17. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-genifibrozil combinaton therapy. JAMA 263:71, 1990.
18. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62:28J, 1988.
19. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained-versus immediate-release niacin in hypercholesterolemic patients. JAMA 271:672, 1991.
20. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR,et al.Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism 34:542, 1985.
21. National Cholesterol Education Program Second Annual Report of the Expert Panel On: Detection. evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 89:1329, 1994.
22. Stem RH, Spence JD, Freeman DJ, Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 50:66, 1991.
23. Counseling the patient with hyperlipidemia. American Heart Association, Bethedesta. MD. Publication 70-061-A, 6-84-50m p. 38-45, 1988.
24. Steiner PM, Freidel J, Bremner WF, Stein EA. Standardization of micromethods for plasma cholesterol, triglyceride, and HDL-cholesterol with the lipid clinics' methodology (abstract). J Clin Chem 19:850, 1981.
25. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart. Lung. and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med 9:105, 1989.
26. Watnick GR, Albers JJ. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 19:65, 1978.
27. Lipid Research Clinics Program. Manual of laboratory operations: Lipid and lipoprotein analysis. Washington. DC: US Dept of Health Education and Welfare. 1982. Publication NIH 75-628.
28. Stein EA, Kreisberg R, Miller V,et al.Effect of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Arch Intern Med 150:341, 1990.
29. Stein EA, DiPersio L, Pesce AJ,et al.Enzyme-linked immunoabsorbent assay of apolipoprotein A-II in plasma using a monoclonal antibody. Clin Chem 32:967, 1986.
30. Miller JA, Stein EA, Kaplan LA. Development of a competitive binding enzyme-linked immunoabsorbent assay (ELISA) for plasma apoprotein E using a monoclonal antibody (Mab). Clin Chem 36:964, 1990.
31. Stein EA, Kumbla L, Miller J, Srivastiva L, Kashyap ML. Development and evaluation of a competitive ELISA for Lp(a). Clin Chem 38:1067, 1992.
32. Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart JC. Differential electroimmunoassay of human Lp A-1 lipoprotein particles on ready-to-use plates. Clin Chem 36:1431, 1990.
33. Pun ML. Combining independent one sample tests of significance. Ann Inst Stat Math 19:285, 1967.
34. Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 74:149, 1994.
35. Davignon J, Roederer G, Montigny M, Hayden MR, Tan MH, Connelly PW,et al.Comparative efficacy and safety of pravastatin, nicotinic acid, and the two combined in patients with hypercholesterolemia. Am J Cardiol 73:339, 1994.
36. Wahlberg G, Walldius G, Olsson AG, Kirstein P. Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyper-lipoproteinaemia. J Intern Med 228:151, 1990.
37. Bard JM, Pam HJ, Camare R, Luc G, Ziegler O, Dachet C, Bruckert E,et al.A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 41:498, 1992.